

Table 3

Wall	T2 mapping in case's affected wall (LGE+) (mean ± SD)	p (a)	T2 mapping in all case's unaffected walls (LGE-) (mean ± SD)	p (b)	T2 mapping of respective wall in controls (mean ± SD)	p (c)
Anterior (n)	53 ± 5 (7)*	0,2955	50 ± 5 (15)**	0,7851	49 ± 3 (18)*	0,0803
Posterior (n)	52 ± 5 (21)*	0,0062	49 ± 4 (71)**	0,6339	49 ± 4 (18)*	0,0760
Lateral (n)	51 ± 5 (15)*	0,2190	49 ± 5 (43)**	0,2245	48 ± 3 (18)*	0,0235
Inferior (n)	49 ± 5 (7)*	0,8068	48 ± 4 (15)**	0,8121	48 ± 4 (18)*	0,6734
Posterior Septum (n)	51 ± 5 (3†)*	0,3317	48 ± 3 (8)**	0,6868	48 ± 3 (18)*	0,1092
Anterior Septum (n)	49 ± 1 (3†)*	0,7519	48 ± 3 (8)**	0,6105	49 ± 3 (18)*	0,9868
General Mean (n)	51 ± 2 (56)**	0,0008	49 ± 4 (74)**	0,9229	49 ± 1 (108)**	<0,0001

a: analysis between T2 mapping in cases by affected wall and T2 mapping in all unaffected walls of the same patients; b: analysis between T2 mapping in all case's unaffected walls and T2 mapping of respective wall in controls; c: analysis between T2 mapping in cases by affected wall and T2 mapping of respective wall in controls. LGE +: presence of late gadolinium enhancement; LGE -: absence of late gadolinium enhancement; SD: standard deviation; n*: number of patients; n** number of walls assessed; †: one wall lost due to image artifact.